Social Media Encourages Eating Addiction

A new international review has shed light on the extensive and often subtle ways that social media platforms expose children and teenagers to ultra-processed food marketing, raising serious concerns about its impact on youth health and global childhood obesity trends.

Published in BMJ Global Health in February 2025, the study highlights how the digital environment is saturated with advertisements for foods high in sugar, salt and fat. These ads, frequently integrated into entertainment content, are designed to be persuasive and often go unnoticed by young audiences. From breakfast cereals and cookies to soft drinks and fast food, unhealthy food promotions are a constant presence in kids’ online lives.

The report examines 80 previous studies involving nearly 20,000 children and teens and shows a strong link between exposure to digital food ads and increased consumption of unhealthy foods. Children not only crave these items more but also pressure their parents into buying them. One study cited revealed that junk food promoted by influencers notably increased immediate food consumption among children aged 9 to 11, unlike healthy food promotions, which had little impact.

Unlike traditional media, social platforms such as TikTok, YouTube and Instagram tailor content using algorithms based on user behavior. Ads are cleverly disguised within games, quizzes and videos, making them difficult for young users to identify as marketing.The researchers noted,

Digital marketing strategies are nearly universally effective in shaping young people’s eating habits and encouraging the consumption of unhealthy foods.

Social media as a commercial determinant of health

The review adds to growing evidence that social media functions as a commercial determinant of health (CDoH), comparable to industries like tobacco and alcohol. These platforms not only facilitate food marketing but also shift public perception and promote corporate agendas.

In the U.S., over 95% of teens have access to a smartphone, and more than a third report near-constant social media use. In the U.K., most children have a phone by age 11, and even children as young as five to seven are active online. Australia recently introduced a ban on social media use for children under 16, reflecting rising concerns.

Researchers note that just like other health-harming industries, the food sector uses social media to resist regulation, co-opt health language, and reshape public discourse. For instance, Australian studies found that processed food companies actively lobbied against public health policies on Twitter while pushing for voluntary measures and using misleading narratives.

This review is the first to focus on how these marketing tactics target youth, deepening health inequalities and contributing to rising rates of non-communicable diseases (NCDs) such as diabetes and heart disease.

Youth flooded with food ads daily

The research team, made up of experts from the U.K., Canada, and New Zealand, analyzed 36 studies and editorials published between 2000 and May 2023. They found that exposure to digital food marketing differs by country, age, and gender.

For instance:

  • In Mexico, children were shown an average of 2.7 food ads per hour on weekdays.
  • Australian teens were exposed to roughly 168 food promotions weekly via mobile devices.
  • In Canada, 72% of youth ages 7-16 saw food marketing within 10 minutes of opening their favorite apps. Of all food ads on popular children’s sites, over 93% promoted high-fat, salty, or sugary products.

Boys were more often targeted with ads centered around sports and performance, while girls received more interactive content, such as quizzes and polls. The platforms often gather and sell user data to companies that harm public health, further complicating efforts to track or regulate ad exposure.

Teenagers, in particular, face the greatest risk, with many studies pointing to a correlation between food marketing, poor body image, and disordered eating patterns. Brands also quickly adapt their marketing strategies to current events. During the COVID-19 pandemic, 14 of the top 20 unhealthy food brands in New Zealand released pandemic-themed promotions to stay relevant.

 WHO and researchers call for stronger regulation

The World Health Organization (WHO) has long warned that aggressive food marketing negatively affects children’s dietary habits. In 2023, it urged countries to adopt strict mandatory rules to shield children from advertisements promoting foods high in sugar, salt, and unhealthy fats.

The current review echoes that call, emphasizing that voluntary industry standards have largely failed. Many current policies don’t reflect the complexities of digital advertising or cover adolescents, who are heavy users of online platforms but often fall outside regulatory definitions of “children.”

In the U.S., regulatory challenges are compounded by First Amendment protections of commercial speech, limiting the government’s ability to restrict harmful marketing practices. Tech companies are even pushing back against state-level efforts—such as Florida’s social media age restriction law — designed to better protect minors.

Researchers stress that traditional rules designed for TV and print media won’t work in today’s digital ecosystem. Instead, they advocate for updated approaches tailored to social media’s unique environment.

 Key recommendations from the study:

  • Define what counts as child-targeted marketing in digital spaces
  • Coordinate internationally to close legal and regulatory gaps
  • Introduce mandatory restrictions on unhealthy food ads targeting minors
  • Implement media literacy programs to build youth awareness
  • Establish better tracking systems for monitoring digital ad exposure

While parental involvement is vital — particularly in teaching children how to recognize and question digital marketing — the authors say structural reform is essential.

“Parents and caregivers should push for policy change,” the study concludes. “Social media is deeply woven into young people’s daily lives, and recognizing the health risks posed by the digital food environment is essential to improving outcomes for children and teens globally.”

Your responses and feedback are welcome!

Source: “Social media is fueling the childhood obesity crisis, global study warns,” U.S. Right to Know, 4/8/25
Source: “The impact of the social media industry as a commercial determinant of health on the digital food environment for children and adolescents: a scoping review,” BMJ Global Health, 2/19/25
Source: “Teens and Internet, Device Access Fact Sheet,” Pew Research Center, 01/05/24
Image by Tim Gouw/Pexels

Zepbound vs. Wegovy, and New Diabetes Study

In the ongoing battle against obesity and type 2 diabetes, two medications — Zepbound (tirzepatide) and Wegovy (semaglutide) — have emerged as leading treatments. Both are FDA-approved and have demonstrated effectiveness in weight management, but they differ in mechanisms, dosage, and overall effectiveness. If you’re considering either of these drugs for weight loss or for weight loss of your kids, here’s what you need to know, according to VeryWellHealth.com.

How do these medications work?

Zepbound and Wegovy belong to a class of medications known as GLP-1 receptor agonists, which help regulate blood sugar levels and metabolism. However, Zepbound (tirzepatide) has an added advantage: It is also a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. This dual action may contribute to greater weight loss and improved blood sugar control compared to semaglutide.

Both drugs slow down gastric emptying, making you feel fuller for longer, which helps reduce appetite and calorie intake. Research suggests that tirzepatide’s additional GIP receptor activation enhances its effectiveness.

Effectiveness for weight loss

Both medications are effective for weight loss, but studies suggest tirzepatide may be superior. Consider these findings:

  • A 2024 study found that patients with obesity or overweight treated with tirzepatide experienced greater weight loss compared to those on semaglutide.
  • A 2023 review revealed that tirzepatide users had an average total body weight loss of 17.8%, compared to 12.4% for semaglutide users.
  • A 2021 study indicated tirzepatide was more effective than semaglutide in reducing blood sugar levels in people with type 2 diabetes over 40 weeks.

 

While these studies indicate tirzepatide’s potential advantages, it is important to note that the dosages in these studies were not always equal, which could impact the results. More direct comparisons are needed to confirm these findings.

Dosage differences

Both medications are taken via weekly subcutaneous injections, but their dosage regimens differ:

Tirzepatide (Zepbound) Dosage:

  • Initial dose: 2.5 mg per week for four weeks
  • Dose increases: Gradual increments of 2.5 mg every four weeks
  • Maximum dose: 15 mg per week

 

Semaglutide (Wegovy) Dosage:

  • Initial dose: 0.25 mg per week for four weeks
  • Dose increases: Gradually up to 0.5, 1.0, 1.7, or 2.4 mg
  • Maximum dose: 2.4 mg once weekly

Side effects and safety

Both medications share common side effects, including:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Decreased appetite
  • Stomach discomfort
  • Fatigue
  • Heartburn

 

Muscle loss has been reported in patients taking both medications, but this can also occur with significant weight loss.

Cost and availability

One major concern for many patients is affordability. The annual cost for GLP-1 receptor agonist drugs can range from $5,000 to $10,000 in the U.S. While tirzepatide tends to be more cost-effective than semaglutide, prices depend on insurance coverage and availability of manufacturer discounts.

Previously, both drugs experienced shortages, leading to increased demand for compounded versions. However, as of February 2025, neither medication was still in shortage.

Can you switch between the two?

Yes, switching between these medications is not uncommon, especially if one is not yielding the desired results. However, a healthcare provider should always guide the transition to ensure safety and effectiveness.

Which one should you choose?

Both Zepbound and Wegovy can effectively aid in weight loss, but the choice depends on individual factors such as:

  • Effectiveness: Tirzepatide may offer superior weight loss benefits.
  • Cost: Tirzepatide tends to be more affordable, but insurance coverage varies.
  • Age Restrictions: Tirzepatide is not currently approved for use in children.
  • Tolerability: Both drugs have similar side effects, but individual experiences may differ.

GLP-1 Drugs for Type 2 diabetes may not be safe for Type 1 patients

Then there’s this. Medications originally developed to manage type 2 diabetes may not be suitable for patients with type 1 diabetes, according to researchers from the Johns Hopkins Bloomberg School of Public Health.

A recent study highlights concerns regarding the use of GLP-1 receptor agonists among type 1 diabetes patients. GLP-1 receptor agonists have been available for over two decades to help manage type 2 diabetes. Over time, some were also approved for reducing cardiovascular disease risk and treating obesity. However, type 1 diabetes patients have started using these drugs even though they were excluded from clinical trials due to concerns about hypoglycemia (dangerously low blood sugar levels).

Unlike type 2 diabetes, which is characterized by insulin resistance, type 1 diabetes is an autoimmune condition where the body does not produce insulin, requiring lifelong insulin therapy. The study, which analyzed over 200,000 anonymized medical records from 2008 to 2023, found a significant increase in obesity rates among individuals with type 1 diabetes across all age groups and ethnic backgrounds.

The findings, published on March 3 in Diabetes, Obesity and Metabolism, emphasize the need for more research on the use of GLP-1 receptor agonists in type 1 diabetes patients. Senior author Dr. Jung-Im Shin, an associate professor at the Bloomberg School’s Department of Epidemiology, commented:

These findings highlight the urgent need for better data — including clinical trials — on the effectiveness and safety of GLP-1 receptor agonists in people with type 1 diabetes, to inform clear guidelines on their use in these patients.

As usual, more studies need to happen, and researchers have their work cut out for them.

Your responses and feedback are welcome!

Source: “Zepbound (Tirzepatide) vs. Wegovy (Semaglutide) for Weight Loss,” VeryWellHealth.com, 3/31/25
Source: “Weight-Loss Drug Use Has Risen Sharply Among Children and Adults With Type 1 Diabetes,” John Hopkins Bloomberg School of Public Health, 3/26/25
Source: “Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States,” Diabetes, Obesity and Metabolism, 3/3/25
Image by Chokniti Khongchum/Pexels

Addressing Pediatric Obesity With Digital Tools and Personalized Care

Currently, one in five children and adolescents in the U.S. has obesity — a rate that has steadily increased over the past decade. Between the early 2010s and 2020, childhood obesity rates rose from 17.7% to 21.5%, according to a study published in JAMA Pediatrics. In response to this growing crisis, the American Academy of Pediatrics (AAP) released updated clinical guidelines in 2023, recommending at least 26 hours of health behavior and lifestyle treatment within three to twelve months. While welcomed by pediatricians, these recommendations posed a significant implementation challenge. Enter Dr. Yum, highlighted in a recent article on Medscape.

Bridging the gap with practical solutions

Dr. Nimali Fernando, a pediatrician in Virginia, understood the difficulties families faced in maintaining a nutritious diet. In the 2010s, she founded Yum Pediatrics, a teaching kitchen and garden that served as a foundation for practical nutrition education. Realizing the potential of digital tools to expand her reach, she transitioned from private practice in 2023 to launch Touchpoints, a multimedia program under Dr. Yum’s umbrella, designed to help clinicians implement the AAP guidelines.

Through step-by-step modules on topics like mindful eating, picky eating, and food insecurity, Touchpoints equips pediatricians with structured conversation guides to engage families. These resources provide a practical solution for overwhelmed healthcare providers who may lack nutrition training but want to offer evidence-based guidance.

The reality of implementing new guidelines

Although the AAP guidelines were well-received, logistical challenges remain. Many pediatric clinics lack access to multidisciplinary teams, leaving primary care providers to shoulder the responsibility of obesity management. Furthermore, insurance companies often do not reimburse for lifestyle and behavior treatment programs, making implementation even more difficult.

To navigate this issue, clinicians bill office visits under comorbid conditions associated with obesity, such as high cholesterol, sleep disturbances, or prediabetes. This approach allows them to provide personalized care while addressing the broader health concerns linked to weight management.

Expanding access through telehealth

Recognizing the importance of accessibility, some pediatricians conduct the Touchpoints program entirely through telehealth. This method aligns better with families’ schedules and fosters a consistent relationship between providers and patients. By meeting monthly, pediatricians can offer ongoing support and track progress effectively.

Telehealth also enables a whole-family approach to weight management. With rising rates of eating disorders post-pandemic, Touchpoints promotes a food-neutral and weight-neutral perspective, reducing stigma and fostering sustainable healthy habits.

Tools for sustainable change

Currently, over two dozen clinicians subscribe to Touchpoints, with researchers from UTHealth Houston launching a study to assess its impact on BMI changes among patients. However, many of the resources remain free through the original Dr. Yum website. One standout feature, the Meal-o-Matic, allows families to create customized recipes based on available ingredients, empowering children to take ownership of their meals. Through meal tracking and photo uploads, children engage with their progress in a supportive, interactive way.

Getting started with pediatric weight management

For pediatricians interested in expanding their approach to obesity care, the AAP offers valuable resources, including staff training on weight bias and stigma. Additionally, the CDC provides a list of evidence-based weight management programs ready for implementation.

Starting small can be an effective strategy. For example, begin with two or three motivated families, using intake forms and food journals to identify those most likely to commit to the process. Naturally, positive outcomes depend on a family’s readiness to engage.

A study on digital health interventions

While digital health strategies may benefit children and adolescents struggling with overweight and obesity, their role in replacing or enhancing components of standard multicomponent care remains uncertain, according to an umbrella review published in Obesity Reviews.

To assess the impact of digital health interventions on weight management in young people, researchers conducted a comprehensive review of existing reviews and meta-analyses. The selected studies focused on the effectiveness and experiences of digital health technologies in managing obesity among children and adolescents (aged 0 to 19) based on the World Health Organization (WHO) criteria.

The review encompassed 16 systematic reviews and 10 meta-analyses, with 15 primarily relying on quantitative data from primary studies. Nine reviews exclusively included randomized controlled trials (RCTs), while the remaining seven incorporated both RCTs and non-RCTs. Most of the primary studies were conducted in high-income regions such as the United States, Europe, and Oceania, with limited representation from middle- and low-income countries.

The number of participants across the included reviews ranged from 195 to 5,777. When evaluating body mass index (BMI) scores, researchers observed small but statistically significant effects of digital interventions on body measurements.

The researchers concluded:

Overall, digital health interventions had a small impact on anthropometric measures when assessing BMI and BMI-z-scores… It remains unclear how these interventions could complement or replace elements of standard care for children and adolescents with overweight or obesity.

It takes a village

Obesity management is not limited to pediatricians alone. Nurses, dietitians, and nutritionists can all play a role in delivering weight management programs. By integrating digital tools, structured programs, and telehealth solutions, pediatricians can make a meaningful impact in the fight against childhood obesity — one family at a time.

Your responses and feedback are welcome!

Source: “Digital Health Interventions May Aid Pediatric Obesity Treatments,” Endocrinology Advisor, 3/18/25
Source: “Digital health interventions to treat overweight and obesity in children and adolescents: An umbrella review,” Obesity Reviews, 2/19/25
Source: “Feeding Change: How Dr. Yum Is Helping Pediatricians Tackle Childhood Obesity One Meal at a Time,” Medscape, 3/21/25
Image by Alex Green/Pexels

Online Weight-Loss Drug Providers Pivot to HRT

In an unexpected twist, the rise of online weight-loss drug providers is driving renewed interest in an older, once-stigmatized treatment: hormone replacement therapy (HRT). As more women seek solutions for menopause-related symptoms, including weight gain, online healthcare platforms are stepping in to fill the gap.

Why the change?

As we’ve previously discussed, regulators declared that popular weight-loss drugs Wegovy and Zepbound are no longer in short supply. As a result, consumers who have relied on less expensive, compounded versions — often obtained through telehealth services or medical spas — will need to find other options.

As reported in Stat,

In the last two years, hundreds of businesses have cropped up to meet the surge in demand for the obesity and diabetes medications known as GLP-1s. The majority prescribe compounded copies of the drugs — a tenuous business strategy as shortages of the branded versions of the medications have come to an end.

Now, some businesses are setting their sights on another opportunity in compounding: hormones.

This leaves consumers potentially having to shell out the big bucks for the branded versions, and telehealth companies finding another cash cow.

As explained in a recent SELF article,

In theory, the FDA’s removal of GLP-1s from its shortage list should mean any patient who needs the brand-name drugs will be able to get them. But it’s more complicated than that. While the compounded options that have been filling the gap aren’t FDA-approved (a red flag), they have been available at much lower prices — making their imminent illegality a potential access issue.

Why this matters

Many women struggling with menopause symptoms find themselves facing a shortage of specialized healthcare providers. Turning to the internet for solutions, they are increasingly discovering comprehensive telemedicine platforms that offer not only GLP-1 weight-loss drugs but also HRT. While this growing market provides convenient access to treatments, it also raises concerns about patient care quality, the safety of compounded medications, and the evolving nature of doctor-patient relationships.

A booming market

The global HRT market was valued at nearly $21 billion in 2022 and is projected to surpass $35 billion by 2030, according to Grand View Research. This rapid growth reflects increasing awareness and acceptance of menopause treatments that were previously difficult to obtain. The demand is also fueled by a broader consumer interest in health and wellness, along with the rising popularity of GLP-1 medications for weight management.

Beth Mosier, a director in West Monroe’s healthcare M&A group, notes that the expansion of GLP-1 offerings has created a natural pathway for integrating HRT. “It coincides with increased consumer demand for more holistic health solutions,” she says.

Major players enter the space 

The weight-loss and wellness industry is quickly adapting to this trend. Earlier this month, Noom announced its entry into the HRT market, joining platforms like Midi, which already offer both GLP-1s and HRT. Additionally, Hims & Hers is expanding its services to include care for perimenopause and menopause.

Women between the ages of 40 and 60 represent a key customer base for Noom, making HRT a strategic addition to their GLP-1 offerings. Noom CEO Geoff Cook says:

As menopause approaches, metabolic shifts occur, altering how the body processes sugars and fat, leading to symptoms like hot flashes, mood changes, and weight gain.

A 2023 Mayo Clinic study published in Menopause found that using HRT alongside GLP-1 drugs like Ozempic and Wegovy resulted in approximately 30% greater total body weight loss than GLP-1s alone. Other studies have echoed these findings, reinforcing the synergy between the two treatments.

The growing role of telehealth

For years, high-end medical aesthetic and wellness clinics have combined GLP-1 and HRT treatments to optimize weight management and overall health. Now, telehealth providers are embracing this model, offering convenient and often more affordable access to these therapies.

Mosier says,

They’re realizing they can address not just weight concerns but also muscle mass, sleep, and quality of life… Telemedicine is catching up to what high-end clinics have been doing for years.

The risks of direct-to-consumer care

Despite the benefits, the surge in direct-to-consumer HRT services comes with risks. Unlike traditional in-person care, online platforms shift more responsibility onto patients, particularly when compounded medications are involved.

Dr. Robert Kauffman, a professor in the Department of Obstetrics and Gynecology at Texas Tech University, acknowledges the positive shift in attitudes toward HRT but raises concerns about the quality of care. He says:

Most of us who specialize in menopausal medicine are pleased that more women are open to hormone therapy… But are these services encouraging women to bypass in-person exams, where critical health information can be uncovered?

The financial incentives driving companies into this space also raise red flags. “There’s a huge profit motive,” Dr. Kauffman warns. “How often are these doctors following up with their patients?”

The bottom line

The intersection of weight-loss treatments and menopause care is creating new opportunities for both patients and healthcare providers. As telehealth platforms expand their offerings, they provide unprecedented access to treatments that were once difficult to obtain.

As with any rapidly growing market, caution is warranted. Women considering these services should weigh the convenience of telemedicine against the benefits of traditional in-person care, ensuring they receive comprehensive and safe treatment.

Your responses and feedback are welcome!

Source: “As GLP-1 compounding stares down a wall, telehealth companies pivot to hormones,” STAT, 3/11/25
Source: “Online GLP-1 sales fuel hormone replacement therapy,” Axios, 3/11/25
Source: “Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.,” SELF, 3/13/25
Image by RDNE Stock project/Pexels

The Lasting Impact of Early-Life Responsive Parenting on Childhood Weight

Childhood obesity remains a pressing public health issue in the United States, with over 22% of children between the ages of six and 19 classified as obese. While diet and exercise are often the focal points of obesity prevention efforts, a new study from the Penn State College of Medicine and the Center for Childhood Obesity Research at Penn State University suggests that responsive parenting during early childhood could play a critical role in shaping long-term weight outcomes.

Insights from the INSIGHT study

The research, part of the ongoing INSIGHT study, explored the effects of early-life parenting interventions on childhood weight. The study followed two groups of first-time mothers and their children from birth through age nine. One group received training on responsive parenting practices, which encouraged mothers to attune to their child’s emotional and physical needs, particularly in areas such as feeding, sleep, play, and emotional regulation. The control group, by contrast, received education on household hazard prevention.

Published in JAMA Pediatrics on March 10, 2025, the study builds upon previous findings that demonstrated a positive impact of responsive parenting on children’s weight through age three. The latest results show that children whose mothers received responsive parenting education had lower average body mass index (BMI) levels through middle childhood compared to their peers in the control group. Notably, the effects were more pronounced among female participants, indicating that this approach may be particularly beneficial for young girls.

The challenges of sustaining early gains

Despite the promising early outcomes, the study revealed that the benefits of responsive parenting interventions diminished over time, with BMI differences fading by age nine. Dr. Ian Paul, principal investigator and University Professor of Pediatrics at the Penn State College of Medicine, emphasized that while the intervention had a meaningful early impact, sustaining these effects in an environment that promotes unhealthy weight gain remains a challenge.

He said:

Our intervention stopped when the participating children were 2 years old and focused on the parenting of young children rather than behaviors and risk factors that emerge among school-aged children… While we are delighted that we made an impact early on, the fact that the beneficial effects disappeared by age 9 is not surprising, given the obesogenic environment we live in.

Dr. Jennifer Savage, another principal investigator and Director of Penn State’s Center for Childhood Obesity Research, echoed this sentiment, highlighting the importance of ongoing support for families beyond early childhood.

A call for a life-course approach

The study’s findings reinforce the notion that diet and exercise alone are not enough to combat childhood obesity. Instead, responsive parenting practices may help establish healthy growth patterns that reduce the risk of obesity as children grow. However, to sustain these benefits, researchers advocate for a broader, life-course approach that includes continued support for healthy habits throughout childhood and adolescence.

By integrating responsive parenting strategies into early childhood care and complementing them with ongoing reinforcement, healthcare providers, educators, and policymakers can help foster healthier futures for children. As this research suggests, equipping parents with the tools to respond to their child’s developmental needs may be an essential component of long-term obesity prevention efforts.

Your responses and feedback are welcome!

Source: “Early-life responsive parenting intervention yields lasting but diminishing benefits on child weight,” Penn State Health News, 3/10/25
Source: “Long-Term Effects of a Responsive Parenting Intervention on Child Weight Outcomes Through Age 9 Years,” JAMA Pediatrics, 3/10/25
“Effect of a Responsive Parenting Educational Intervention on Childhood Weight Outcomes at 3 Years of Age: The INSIGHT Randomized Clinical Trial,” PubMed, 8/7/18
Image by Vanessa Loring/Pexels

FDA Ends Compounding for Popular GLP-1 Drugs

 

Due to limited availability and high costs, many Americans have turned to compounding pharmacies for weight-loss medications. However, this alternative will soon be unavailable.

Federal regulations allow compounding pharmacies to produce copies of drugs during shortages. Recently, though (as it’s been widely reported) regulators declared that popular weight-loss drugs Wegovy and Zepbound are no longer in short supply. As a result, consumers who have relied on less expensive, compounded versions — often obtained through telehealth services or medical spas — will need to find other options.

This has left patients like Amanda Bonello, a mother of three from Marion, Iowa, feeling anxious. She has been using a compounded version of tirzepatide, the active ingredient in Eli Lilly’s Mounjaro (for diabetes) and Zepbound (for weight loss). With Zepbound’s retail price averaging nearly $1,300/month, Bonello fears she won’t be able to afford the brand-name drug.

She said,

It feels like we’re stranded while Big Pharma controls the only food supply, letting those who can’t pay go without.

In response, industry groups representing compounding pharmacies and suppliers have filed lawsuits to continue selling these medications. Meanwhile, patients have launched an online petition urging regulators to extend the use of compounded GLP-1 drugs, approve generic alternatives, or push pharmaceutical companies to lower prices. The petition also calls for health insurers to cover these medications.

What’s the status of compounded Wegovy and Zepbound?

Soon, compounding pharmacies will no longer be permitted to produce and sell these weight-loss drugs for widespread use. The government has set a transition period, with compounded versions of Zepbound and Mounjaro already being phased out. Compounded semaglutide (found in Wegovy and Ozempic) will remain available for a short time longer.

In December, the FDA announced that tirzepatide was no longer in shortage, giving pharmacies until February 18 to stop compounding, distributing, or dispensing the drug. Suppliers selling bulk batches have until March 19 to cease distribution. The Outsourcing Facilities Association, an industry trade group, has sued the FDA in Texas to delay enforcement of these restrictions.

In response, the FDA has asked the court to deny the request, arguing that upholding its decision would protect patients and align with Congress’ goal of encouraging drug development while permitting compounding only in temporary shortages.

Last month, the FDA also determined that Novo Nordisk’s semaglutide supply had stabilized. Pharmacies must stop selling compounded semaglutide by April 22, while suppliers must halt distribution by May 22.

What should patients who take compounded weight-loss drugs expect?

Pharmacists supplying compounded weight-loss and diabetes drugs are already informing customers about the upcoming changes. Some have stopped refilling prescriptions, while others are hesitant to start new patients on compounded versions, knowing they will soon need to switch to the brand-name medications.

A study found that within a year of stopping semaglutide, a group of 327 patients from the U.S., Europe, and Japan regained two-thirds of the weight they had lost while on the drug. The study also reported a decline in their overall health.

Jennifer Burch, an independent compounding pharmacist in North Carolina, educates her patients about how compounded drugs are only available when the FDA deems the brand-name versions to be in shortage.

She frequently hears from people interested in starting on compounded tirzepatide. But with the shortage ending, she advises against it if they cannot afford the brand-name medication long-term.

She said:

We want to be upfront with them… We don’t want them to feel abandoned.

Some patients are asking doctors for long-term prescriptions to stockpile the medication for up to a year. However, doctors are reluctant, as they need to monitor patients’ weight loss and overall health.

Burch said:

I had a provider tell me yesterday, ‘I’m worried about writing a 12-month prescription. What if the patient comes back weighing 100 pounds? That’s not the goal.

Are efforts being made to lower brand-name weight-loss drug prices?

Most major employers and private insurers cover diabetes medications like Ozempic and Mounjaro. However, fewer than half of large employers cover GLP-1 medications for obesity. As a result, many patients must pay out of pocket for drugs that can cost about $1,300 per month before discounts.

Congress has scrutinized pharmaceutical companies over the high costs of these drugs, prompting some manufacturers to introduce discounted options.

Eli Lilly reduces price for Zepbound

As was reported by major media outlets, including Reuters, Eli Lilly reduced the cash price for lower-dosage vials of Zepbound through its LillyDirect website. A one-month supply of 2.5 mg now costs $349, while the 5 mg version is priced at $499. Higher dosages (7.5 mg and 10 mg) are now $599 and $699 per month, respectively, with an initial discount to $499 for the first fill and refills within 45 days.

Meanwhile, legal battles over the FDA’s decision continue. The Outsourcing Facilities Association recently sued the agency again, challenging the determination that Wegovy and Ozempic are no longer in shortage. The group had previously sued over the ruling on tirzepatide.

In the tirzepatide lawsuit, the OFA argued that the FDA’s decision effectively created a new rule without proper regulatory procedures. The court has not yet issued a ruling, and the FDA has stated it will hold off enforcing the February 18 deadline until the court decides.

For Bonello, the FDA’s declaration means she must now explore other options. Initially, she had hoped to switch to compounded semaglutide, but she realizes that’s only a temporary fix.

Her employer-sponsored insurance covers GLP-1 medications for diabetes but not for weight loss. Since she doesn’t have diabetes — though her blood sugar is elevated, and her family has a history of the disease — she isn’t eligible for coverage.

Even with Eli Lilly’s discounted $499 price for higher dosages, Bonello says she still can’t afford it while covering her other expenses.

“That’s more than my phone bill and car insurance combined,” she said.

Your responses and feedback are welcome!

Source: “These discounted versions of popular weight-loss drugs are going away: What to know,” USA TODAY, 3/2/25
Source: “Lilly offers weight-loss drugs in vials at a discount to fight competition,” Reuters, 2/25/25
Image by Anna Shvets/Pexels

Greaux Healthy Releases Childhood Obesity Prevention Toolkit

Childhood obesity is a growing concern across the nation, with Louisiana ranking third in the country for prevalence. Addressing this public health crisis requires a multifaceted approach rooted in evidence-based care and practical resources. Recognizing this urgent need, Greaux Healthy, a public service initiative powered by LSU’s Pennington Biomedical Research Center in collaboration with the State of Louisiana, has launched the Childhood Obesity Prevention, Evaluation, and Treatment Toolkit.

This comprehensive resource is designed to equip healthcare providers with the latest scientific evidence and actionable strategies to prevent, evaluate, and treat childhood obesity and its related comorbidities. Developed in alignment with the 2023 American Academy of Pediatrics (AAP) clinical practice guidelines, the toolkit serves as a quick-reference guide that can be seamlessly integrated into various pediatric healthcare settings across Louisiana.

A practical, evidence-based approach

The Childhood Obesity Prevention, Evaluation, and Treatment Toolkit synthesizes the latest research into a streamlined resource, offering clear and practical guidance for healthcare professionals. Dr. Amanda Staiano, Director of Pennington Biomedical’s Pediatric Obesity and Health Behavior Laboratory and a key contributor to the toolkit, highlights its significance:

The comprehensive nature of this toolkit provides pediatricians with a quick reference for evaluating childhood obesity and its comorbidities and approaches for treating children and adolescents with overweight and obesity, all grounded in scientific evidence.

The toolkit’s user-friendly format allows providers to efficiently integrate scientifically validated protocols into their clinical routines, ensuring early intervention and improved health outcomes for children.

Key features of the toolkit

  • Rapid Evaluation Protocols: Simplified guidelines for assessing obesity and associated health risks.
  • Step-by-Step Treatment Strategies: Evidence-based recommendations for behavioral counseling, pharmacotherapy, and referrals for advanced care when needed.
  • Family-Centered Tools: Resources to support sustainable lifestyle changes for children and their families.

 

Pennington Biomedical Medical Investigator Dr. Stewart T. Gordon, FAAP, underscores the importance of the toolkit in addressing a statewide health challenge:

The Greaux Healthy team looks forward to working with all Louisiana pediatric health care professionals — including pediatricians, family physicians, nurse practitioners, physician assistants, dieticians, behavioral health providers, nurses, and health educators — to improve access to prevention, evaluation, and treatment of childhood obesity.

A call to action

Dr. John Kirwan, Executive Director of Pennington Biomedical, reinforces the urgency of this initiative:

Waiting or delaying treatment is not an option when it comes to childhood obesity. Our goal is to provide health care providers with the tools they need to make informed decisions and offer comprehensive, effective treatment to improve the health and future of our children.

With childhood obesity being a chronic disease affecting thousands of Louisiana children, the launch of this toolkit marks a critical step forward in improving pediatric healthcare. By equipping providers with the necessary resources, Greaux Healthy and Pennington Biomedical are fostering a healthier future for children and families across the state.

Healthcare professionals are encouraged to utilize this free, evidence-based resource to enhance their clinical practice and help combat childhood obesity effectively. You can download it here.

Your responses and feedback are welcome!

Source: “New toolkit empowers health care providers with evidence-based strategies for childhood obesity prevention and treatment,” Medical XPress, 2/20/25
Image by Katrin Bolotsova/Pexels

New Study Finds Self-Guided Family-Based Treatment Effective for Childhood Obesity

Childhood obesity is a growing concern worldwide, with one in five children in the U.S. affected. In southern Italy, four in 10 children are overweight despite it being the birthplace of the highly praised Mediterranean Diet. And South Korea is now has the highest obesity rate in East Asia among children and adolescents. And that’s just in the news this week. The list grows and grows.

While traditional obesity treatment methods have been effective, they often come with significant barriers, such as time commitment, cost, and access to specialized care. However, a new clinical trial from UC San Diego suggests that a self-guided version of Family-Based Treatment (FBT) could be a game-changer, offering a more accessible, affordable, and equally effective alternative.

What is family-based treatment?

FBT is a well-established approach to treating childhood obesity that involves working closely with families to promote healthier behaviors. Traditionally, healthcare professionals guide families through a structured program focused on encouraging physical activity, teaching healthy eating habits, and developing age-appropriate behavioral skills.

The new study from UC San Diego’s Center for Healthy Eating and Activity Research (CHEAR) found that self-guided FBT provides the same benefits while reducing the time, cost, and scheduling constraints associated with clinician-led programs.

A more flexible, cost-effective approach

Dr. Kerri Boutelle, senior study author and director of CHEAR, highlighted the limitations of traditional FBT:

While effective, it can be time-intensive, expensive, and offered at limited times, making it difficult for many families to participate.

In contrast, self-guided FBT condenses the program significantly. Instead of the traditional 26 hours of treatment over six months, the self-guided model requires only five hours of treatment within the same timeframe. Families complete 20-minute sessions every other week without the need for a trained clinician, making it a viable option for busy households and those facing financial challenges.

The importance of family involvement

Unlike adult obesity, which is often addressed individually, research shows that a family-based approach is most effective for children. Traditional FBT typically involves parents and their children (ages 8-15) in small group sessions, fostering a supportive environment. However, Dr. Boutelle’s research suggests that direct work with parents — rather than relying on group sessions or extensive clinician involvement — is the key to success.

She said:

While some families may benefit from the standard approach, providing more flexible and accessible alternatives like self-guided FBT can help us make a wider impact on childhood obesity.

Dr. Boutelle emphasized that this model allows treatment to be delivered in medical offices, enabling physicians and healthcare providers to support families without requiring extensive training.

Addressing the complexity of childhood obesity

Obesity in children is a multifaceted issue influenced by diet, physical activity, genetics, and environmental factors. Key contributors include:

  • Diet: High consumption of sugary drinks, processed foods, and large portion sizes.
  • Physical Activity: Sedentary lifestyles, excessive screen time, and limited exercise.
  • Genetics: Some children may be genetically predisposed to weight gain.
  • Environment: Accessibility to unhealthy foods, lack of safe spaces for physical activity, and social norms promoting sedentary habits.

 

With obesity linked to serious health concerns such as type 2 diabetes, high blood pressure, and mental health issues, accessible and effective treatments are crucial. The self-guided FBT model offers a promising solution, making evidence-based care more widely available to families who might otherwise struggle to access traditional programs.

Looking ahead

The findings from UC San Diego’s research underscore the need for innovative approaches to tackling childhood obesity. By offering a flexible, cost-effective, and family-centered solution, self-guided FBT has the potential to reach more families and create lasting health improvements for children nationwide.

As Dr. Boutelle puts it:

There’s no reason to require extensive in-person treatment when we can achieve the same results in a way that fits into families’ lives more easily. Our goal is to ensure that more children receive the help they need without unnecessary barriers.

With ongoing efforts to expand awareness and accessibility, self-guided FBT could soon become a standard tool in the fight against childhood obesity.

Your responses and feedback are welcome!

Source: “UC San Diego clinical trial: Family-based treatment best for obese children,” SDNews.com, 2/14/25
Image by Agung Pandit Wiguna/Pexels

Can New Weight-Loss Drugs Surpass The Current Ones?

Are the weight loss medications currently on the market possibly being overused or not used as intended? Yes and yes. The article published in Axios, “Wegovy and Ozempic stars dim amid overuse concerns,” quotes a few specialists voicing their concern. One of them is Peter Antall, chief medical officer of digital chronic health company Lark. He says,

There is almost like a backlash kind of a sentiment going on… I don’t believe that we’re having second thoughts about the power of the medication. But I think the shine is coming off how they’re being used in real practice… That’s where many of us are concerned.

Another expert is obesity specialist and gastroenterologist Dr. Christopher McGowan, who penned his opinion in MedPage Today. He explained why his “perspective has shifted based on real-world experience.” Dr. McGowan is “deeply concerned about how GLP-1 medications are being used.” He writes:

The benefits of these drugs cannot be denied when they are taken as intended — meaning indefinitely. But what happens to the body and mind when these medications are discontinued? This is where the problem lies…

Noting that “from an efficacy standpoint, these drugs ‘work’,” but only for those who can “afford, tolerate, and sustain GLP-1.” They lose weight and enjoy other benefits such as improvements in various conditions, including kidney disease, sleep apnea, osteoarthritis — the list goes on. However, Dr. McGowan’s parting words send a chill:

 I fear we will look back on this era — after patients have spent tens of thousands of dollars, endured uncomfortable and sometimes serious side effects and experienced recurring weight gain and resurgent food noise — and ask: Even if these drugs ‘work,’ did they really work? Or did they ultimately harm our patients, our society, and our economy? It’s a sobering thought, but one I fear is all too real.

New kids on the block

Pharmaceutical companies are fully aware of current concerns and are actively testing a new wave of weight-loss medications, or planning more trials for the current ones, with a goal of enhancing their effectiveness and offering additional health benefits beyond shedding pounds.

Current treatments like Ozempic and Wegovy, which contain semaglutide — a GLP-1 receptor agonist that helps regulate blood sugar and appetite, are expensive, require weekly injections, and must be taken long-term to prevent weight regain. Drug makers hope that new alternatives will overcome these challenges. Plus, the global market keeps expanding and the demand is surging, so we are sure Big Pharma sees the dollar signs as well.

Let’s take a quick look at what medications we should expect to improve, and what the manufacturers and the researchers plan for them in 2025, as outlined in a recent article published in Nature.

Tirzepatide

Tirzepatide, marketed as Mounjaro and Zepbound, activates both GLP-1 and another hormone, GIP, which plays a role in fat metabolism. In clinical trials, it helped participants lose up to 20% of their body weight over 72 weeks, outperforming semaglutide, which leads to about 15% weight loss in a similar timeframe. Additionally, tirzepatide reduced heart weight, lowered fat around the heart, improved mobility, and decreased blood pressure and inflammation.

A major trial set to conclude in 2025 will explore its impact on heart disease in people with obesity and diabetes.

Retatrutide

Developed by Eli Lilly, retatrutide stimulates GLP-1, GIP, and glucagon receptors, showing even greater potential than existing drugs. In trials, participants lost an average of 24% of their body weight over 11 months. This medication also helped regulate blood sugar in diabetics and is now in phase III trials, expected to conclude by 2026.

Experts believe that combination therapies like retatrutide could be particularly effective, as obesity is a complex condition that benefits from targeting multiple biological pathways.

Orforglipron

Unlike Ozempic, which requires injection, orforglipron is a daily pill that mimics GLP-1’s effects. In early trials, it led to a 10% weight loss over 26 weeks while improving blood pressure and reducing circulating fat molecules.

Eli Lilly anticipates completing phase III trials in 2025, with potential U.S. regulatory approval in 2026. Experts suggest that if oral drugs like orforglipron prove effective, they could disrupt the market by offering a more convenient and cost-effective option.

MariTide

Amgen’s experimental drug MariTide, which stimulates GLP-1 while inhibiting GIP activity, is designed to be taken via monthly injections. In a 52-week study, it resulted in up to 20% weight loss. Unlike other treatments, MariTide appears to help maintain weight loss for months after stopping the medication, an issue seen with semaglutide and tirzepatide.

This potential for sustained results could make it a more attractive option for patients reluctant to commit to lifelong treatment.

CagriSema

Novo Nordisk’s CagriSema, a blend of semaglutide and cagrilintide, has shown superior weight-loss outcomes compared to its individual components. A 68-week study saw participants lose approximately 23% of their body weight.

Muscle preservation and metabolic treatments

Several companies are exploring synthetic amylin-based therapies, which help regulate appetite and blood sugar while preserving muscle mass — an advantage over GLP-1 drugs, which can lead to muscle loss. Novo Nordisk’s amycretin, a combination of GLP-1 and amylin, led to a 22% weight reduction in just 36 weeks.

Another experimental drug, enobosarm, developed by Veru, was found to preserve muscle in older adults with obesity when combined with Wegovy. Future studies may investigate how to help older or frail individuals lose weight while maintaining muscle strength and preventing osteoporosis.

Emerging therapies targeting cannabinoid receptors, which influence hunger, have shown early promise, with more research expected in 2025.

The bottom line

Looking ahead, researchers hope to shift the focus from simple weight loss to a broader understanding of obesity as a metabolic disease. Some believe that the next major breakthrough could come from a treatment that addresses inflammation, a key factor in obesity — though results from human trials are still a long way off.

Even if these new treatments aren’t widely available in 2025, researchers believe that the coming year will provide key insights into which therapies will be most effective and accessible in the near future.

Your responses and feedback are welcome!

Source: “The weight-loss drugs being tested in 2025: will they beat Ozempic?,” Nature, 2/6/25
Source: “Wegovy and Ozempic stars dim amid overuse concerns,” Axios, 2/11/25
Source: “I No Longer Think GLP-1s Are the Answer,” MedPage Today, 1/30/25
Image by Chokniti Khongchum/Pexels

Unlocking Brown Fat’s Power: A New Strategy Against Obesity

A groundbreaking study from the National Cancer Research Centre (CNIO) has revealed an innovative approach to combating obesity by enhancing the body’s natural ability to generate heat. Researchers have discovered that blocking the mitochondrial protein MCJ in brown fat significantly increases thermogenesis, leading to weight loss in obese mice and providing protection against obesity-related diseases such as diabetes. The study was recently highlighted in SciTechDaily.

Obesity and its global impact

Obesity is a pressing global health issue, affecting over 650 million people and contributing to the rise of cardiometabolic diseases and cancer risk. The study, led by Guadalupe Sabio from CNIO and Cintia Folgueira from CNIO and the National Centre for Cardiovascular Research (CNIC), sheds light on a crucial biological mechanism that could pave the way for new therapeutic strategies.

The role of MCJ in energy metabolism

At the heart of this discovery is MCJ, a mitochondrial protein that regulates energy production within cells. The researchers found that eliminating MCJ in obese mice led to a marked increase in heat production, resulting in significant weight loss. Furthermore, the transplantation of MCJ-deficient fat tissue into obese mice also triggered weight reduction, underscoring the protein’s pivotal role in metabolic regulation.

Understanding brown fat and thermogenesis

Adipose tissue, commonly known as body fat, is not merely a passive energy reservoir but an active participant in metabolic regulation. There are two primary types of adipose tissue. White adipose tissue (WAT), which primarily stores energy. Brown adipose tissue (BAT) is rich in mitochondria and specializes in thermogenesis — the process of generating heat in response to cold and other stimuli.

The authors write in Nature Communications:

Obesity is the result of either excessive food intake or inadequate total energy expenditure. We now know that adipose tissue –body fat–, in addition to storing energy, plays a crucial role in the management of that energy by the body. Adipose tissue is a complex organ that acts as a regulator of the whole body’s metabolism, and therefore modulating its function could well be a way to combat obesity.

For years, scientists have sought ways to activate brown fat as a means to combat obesity. “Understanding how brown fat generates heat is essential if we want to leverage it as a tool against obesity,” explains Sabio. The CNIO study now identifies MCJ as a key player in this process.

A new path to weight loss and disease prevention

By blocking MCJ, brown fat burns more energy, leading not only to weight loss but also to improved metabolic health. Mice lacking MCJ in their brown fat exhibited protection against common obesity-related health issues, including diabetes and high blood lipid levels. According to lead researcher Beatriz Cicuéndez, this protection is attributed to the activation of the catabolic pathway — a vital metabolic route that enhances fat, sugar, and protein consumption to produce heat.

Future therapeutic potential

The findings highlight MCJ as a promising therapeutic target for obesity treatment. However, before moving to clinical applications, further research is necessary to assess whether MCJ plays critical roles in other tissues. Additionally, scientists are investigating how changes in fat metabolism might influence cancer progression or conditions like cachexia, a syndrome characterized by extreme muscle and fat loss.

Looking ahead

This discovery opens up exciting possibilities for developing new obesity treatments that harness the body’s natural energy-burning mechanisms. By targeting MCJ, researchers may unlock a novel approach to weight management and metabolic disease prevention, bringing hope to millions struggling with obesity worldwide.

Your responses and feedback are welcome!

Source: “Goodbye Obesity: Scientists Uncover Fat-Burning Protein Switch,” SciTechDaily, 1/27/25
Source: “Absence of MCJ/DnaJC15 promotes brown adipose tissue thermogenesis,” Nature Communications, 1/13/25
Image by Total Shape/Pexels

FAQs and Media Requests: Click here…

Profiles: Kids Struggling with Weight

Profiles: Kids Struggling with Obesity top bottom

The Book

OVERWEIGHT: What Kids Say explores the obesity problem from the often-overlooked perspective of children struggling with being overweight.

About Dr. Robert A. Pretlow

Dr. Robert A. Pretlow is a pediatrician and childhood obesity specialist. He has been researching and spreading awareness on the childhood obesity epidemic in the US for more than a decade.
You can contact Dr. Pretlow at:

Presentations

Dr. Pretlow’s invited presentation at the American Society of Animal Science 2020 Conference
What’s Causing Obesity in Companion Animals and What Can We Do About It

Dr. Pretlow’s invited presentation at the World Obesity Federation 2019 Conference:
Food/Eating Addiction and the Displacement Mechanism

Dr. Pretlow’s Multi-Center Clinical Trial Kick-off Speech 2018:
Obesity: Tackling the Root Cause

Dr. Pretlow’s 2017 Workshop on
Treatment of Obesity Using the Addiction Model

Dr. Pretlow’s invited presentation for
TEC and UNC 2016

Dr. Pretlow’s invited presentation at the 2015 Obesity Summit in London, UK.

Dr. Pretlow’s invited keynote at the 2014 European Childhood Obesity Group Congress in Salzburg, Austria.

Dr. Pretlow’s presentation at the 2013 European Congress on Obesity in Liverpool, UK.

Dr. Pretlow’s presentation at the 2011 International Conference on Childhood Obesity in Lisbon, Portugal.

Dr. Pretlow’s presentation at the 2010 Uniting Against Childhood Obesity Conference in Houston, TX.

Food & Health Resources